Elevated levels of S100B, tau and pNFH in cerebrospinal fluid are correlated with subtypes of Guillain–Barré syndrome

详细信息    查看全文

• 作者：Xiao-Ke Wang (1) (2) (3)
  Hong-Liang Zhang (2)
  Fan-Hua Meng (1)
  Ming Chang (1)
  Yu-Zhi Wang (1)
  Tao Jin (1)
  Eilhard Mix (4)
  Jie Zhu (1) (2)
  
• 关键词：Acute inflammatory demyelinating polyneuropathy ; Acute motor axonal neuropathy ; Guillain–Barré syndrome ; Phosphorylated neurofilament heavy protein ; S100B ; Tau
• 刊名：Neurological Sciences
• 出版年：2013
• 出版时间：May 2013
• 年：2013
• 卷：34
• 期：5
• 页码：655-661
• 全文大小：276KB
• 参考文献：1. Hahn AF (1998) Guillain-Barré syndrome. Lancet 352:635-41 CrossRef
  2. Vucic S, Kiernan MC, Cornblath DR (2009) Guillain-Barré syndrome: an update. J Clin Neurosci 16:733-41 CrossRef
  3. Brettschneider J, Petzold A, Süssmuth S, Tumani H (2009) Cerebrospinal fluid biomarkers in Guillain-Barré syndrome—where do we stand? J Neurol 256:3-2 CrossRef
  4. Van Den Bergh PY, Piéret F (2004) Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 29:565-74 CrossRef
  5. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM (1978) Controlled trial prednisolone in acute polyneuropathy. Lancet 2:750-53 CrossRef
  6. Prineas JW (1981) Pathology of the Guillain-Barré syndrome. Ann Neurol 9(suppl):6-9 CrossRef
  7. Hughes RA, Cornblath DR (2005) Guillain-Barré syndrome. Lancet 366:1653-666 CrossRef
  8. Hafer-Macko C, Hsieh ST, Li CY et al (1996) Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol 40:635-44 CrossRef
  9. Van Doorn PA, Ruts L, Jacobs BC (2008) Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 7:939-50 CrossRef
  10. Mokuno K, Kiyosawa K, Sugimura K et al (1994) Prognostic value of cerebrospinal fluid neuron specific enolase and S-100b protein in Guillain-Barré syndrome. Acta Neurol Scand 89:27-0 CrossRef
  11. Süssmuth SD, Reiber H, Tumani H (2001) Tau protein in cerebrospinal fluid (CSF): a blood-CSF barrier related evaluation in patients with various neurological diseases. Neurosci Lett 300:95-8 CrossRef
  12. Jin K, Takeda A, Shiga Y et al (2006) CSF tau protein: a new prognostic marker for Guillain-Barré syndrome. Neurology 67:1470-472 CrossRef
  13. Petzold A, Keir G, Green AJ, Giovannoni G, Thompson EJ (2003) A specific ELISA for measuring neurofilament heavy chain phosphoforms. J Immunol Methods 278:179-90 CrossRef
  14. Singh P, Yan J, Hull R et al (2011) Levels of phosphorylated axonal neurofilament subunit H (pNFH) are increased in acute ischemic stroke. J Neurol Sci 304:117-21 CrossRef
  15. Yang YR, Liu SL, Qin ZY et al (2008) Comparative proteomics analysis of cerebrospinal fluid of patients with Guillain-Barré syndrome. Cell Mol Neurobiol 28:737-44 CrossRef
  16. Merkies IS, Schmitz P, Van Der Meche FG et al (2002) Quality of life complements traditional outcome measures in immune-mediated polyneuropathies. Neurology 59:84-1 CrossRef
  17. Petzold A, Hinds N, Murray NM et al (2006) CSF neurofilament levels: a potential prognostic marker in Guillain-Barré syndrome. Neurology 67:1071-073 CrossRef
  18. Petzold A, Brettschneider J, Jin K et al (2009) CSF protein biomarkers for proximal axonal damage improve prognostic accuracy in the acute phase of Guillain-Barré syndrome. Muscle Nerve 40:42-9 CrossRef
  
• 作者单位：Xiao-Ke Wang (1) (2) (3)
  Hong-Liang Zhang (2)
  Fan-Hua Meng (1)
  Ming Chang (1)
  Yu-Zhi Wang (1)
  Tao Jin (1)
  Eilhard Mix (4)
  Jie Zhu (1) (2)
  
  1. Department of Neurology, The First Hospital of Jilin University, Changchun, China
  2. Division of Neurodegeneration, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Novum, plan 5, 141 86, Stockholm, Sweden
  3. Department of Neurosurgery, The Second Hospital of Jilin University, Changchun, China
  4. Department of Neurology, University of Rostock, Rostock, Germany
  
• ISSN：1590-3478

文摘

Guillain–Barré syndrome (GBS) is an immune-mediated inflammatory disease in the peripheral nervous system. Specific biomarkers for the two most common clinical subtypes of GBS, i.e., acute inflammatory demyelinating polyneuropathy (AIDP) and acute motor axonal neuropathy (AMAN) are still missing. The distinctive pathological features of AIDP and AMAN may lead to release of such specific biomarkers including glial markers (calcium-binding astroglial protein, S100B) and axonal damage markers [axoskeletal protein, phosphorylated neurofilament heavy protein (pNFH); cytoskeletal protein, tau], etc. To explore the potentials of biochemical markers for differential diagnosis and evaluation of prognosis of clinical subtypes in GBS, we used ELISA to measure the levels of S100B, tau and pNFH in serum and cerebrospinal fluid (CSF) from the patients with AIDP, AMAN, viral encephalitis and other non-inflammatory neurological disorders (OND), respectively. The values of albumin quotient and IgG index in CSF are significantly higher in AIDP and AMAN than in OND. The levels of S100B, tau and pNFH in serum and CSF are elevated in the patients with AIDP and AMAN compared to OND. The concentrations of these proteins are all higher in CSF than in serum. Increased levels of S100B in CSF at the acute phase are positively correlated with the GBS disability scale scores (GDSs) in AIDP, whereas enhanced levels of tau and pNFH in CSF are positively correlated with the GDSs in AMAN. Increased CSF levels of S100B, tau and pNFH at the acute phase may predict a poor prognosis and evaluate the severity of AIDP or AMAN at plateau and the recovery phase. Elevated levels of pNFH in CSF may be used for differentiating between AMAN and AIDP.